Evidence map›Paper›PMID 22226862›Full record

ArticleVaccine2012

Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling.

Evandro R Winkelmann, Douglas G Widman, Jingya Xia, Tomohiro Ishikawa, Mindy Miller-Kittrell, Michelle H Nelson, Nigel Bourne, Frank Scholle, Peter W Mason, Gregg N Milligan

Abstract read
In one paragraph

Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Evandro R WinkelmannDepartment of Pathology, UTMB, Galveston, TX 77555, USA.
Douglas G Widman
Jingya Xia
Tomohiro Ishikawa
Mindy Miller-Kittrell
Michelle H Nelson
Nigel Bourne
Frank Scholle
Peter W Mason
Gregg N Milligan
The University of Texas Medical Branch at Galveston · USNorth Carolina State University · USGalveston College · USJohn Sealy Hospital · US

Funding

Innate Immune Recognition Enhances Flavivirus Vaccine EfficacyU01AI082960 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MILLIGAN, GREGG N. · 2009 to 2010
$1.2M
Dendritic Cell Targeting Enhances Flavivirus Vaccine EfficacyR21AI077077 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MILLIGAN, GREGG N. · 2007 to 2009
$642k
NIAID NIH HHS R21 AI077077NIAID NIH HHS U01 AI082960NIAID NIH HHS UO1 AI082960
6 · The paper itself

Abstract

Type I interferons (IFNs) are critical for controlling pathogenic virus infections and can enhance immune responses. Hence their impact on the effectiveness of live-attenuated vaccines involves a balance between limiting viral antigen expression and enhancing the development of adaptive immune responses. We examined the influence of type I IFNs on these parameters following immunization with RepliVAX WN, a single-cycle flavivirus vaccine (SCFV) against West Nile virus (WNV) disease. RepliVAX WN-immunized mice produced IFN-α and displayed increased IFN-stimulated gene transcription in draining lymph nodes (LN). SCFV gene expression was over 100 fold-higher on days 1-3 post-infection in type I IFN receptor knockout mice (IFNAR(-/-)) compared to wild-type (wt) mice indicating a profound IFN-mediated suppression of SCFV gene expression in the wt animals. IFNAR(-/-) mice produced nearly equivalent levels of WNV-specific serum IgG and WNV-specific CD4(+) T cell responses compared to wt mice. However, significantly higher numbers of WNV-specific CD8(+) T cells were produced by IFNAR(-/-) mice and a significantly greater percentage of these T cells from IFNAR(-/-) mice produced only IFN-γ following antigen-specific re-stimulation. This altered cytokine expression was not associated with increased antigen load suggesting the loss of type I IFN receptor signaling was responsible for the altered quality of the CD8(+) effector T cell response. Together, these results indicate that although type I IFN is not essential for the intrinsic adjuvanting of RepliVAX WN, it plays a role in shaping the cytokine secretion profiles of CD8(+) effector T cells elicited by this SCFV.

Indexed as

Signal TransductionAdjuvants, ImmunologicAnimalsAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesImmunoglobulin GLymph NodesMiceMice, Inbred C57BLMice, KnockoutReceptor, Interferon alpha-betaWest Nile FeverWest Nile Virus VaccinesAdjuvants, ImmunologicAntibodies, ViralImmunoglobulin GReceptor, Interferon alpha-betaWest Nile Virus Vaccines

Identifiers

PMID22226862
PMCPMC3274573
OpenAlexW2015567689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.